Cancer News

Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer (03/16/2017)

The US Food and Drug Administration (FDA) has approved the investigational drug Kisqali® (ribociclib, LEE011) for first line treatment of hormone receptor + HER 2- metastatic breast cancer because when combined with Femera (letrozole) the combination benefits all such women and leads to improved survival without cancer recurrence. The interim results from a large clinical …

Continue reading "Kisqali® Receives FDA Approval as First Line Treatment for HR+/HER2- Metastatic Breast Cancer"

Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer (01/09/2017)

The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced following prior therapies. These results were recently presented at the 2016 annual San Antonio Breast Cancer Symposium (SABCS). Approximately 12% of breast cancers are triple-negative breast cancers, …

Continue reading "Keytruda®/Halaven® Combo May Be Effective in Advanced Triple-Negative Breast Cancer"

Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer (10/26/2016)

The investigational drug ribociclib (formerly LEE011) when combined with Femera (letrozole) for the initial treatment of postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer leads to improved survival without cancer recurrence. The interim results from a large clinical trial presented at the 2016 European Society for Medical Oncology (ESMO) meeting and published in the … Continue reading "Ribociclib Offers ‘Paradigm Shift’ in Advanced Breast Cancer"

ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer (09/05/2016)

The American Society of Clinical Oncology (ASCO) recently convened an Expert Panel to create recommendations for endocrine therapy for women with hormone-receptor (HR)-positive, metastatic breast cancer. The panel conducted “a systematic review of evidence from 2008 through 2015 to create recommendations informed by that evidence.” These updates were recently published in the Journal of Clinical … Continue reading "ASCO Treatment Recommendations for HR+, Metastatic Breast Cancer"

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06/30/2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These results were recently reported at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Approximately 10-20% of breast cancers are referred to … Continue reading "Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer"

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (06/22/2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). One large challenge in furthering research in the field of cancer is obtaining enough samples of tumor tissue … Continue reading "Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study"

Abemaciclib Promising in Advanced Breast Cancer (06/07/2016)

The investigative agent abemaciclib, which is still in clinical trials, appears promising in providing anti-cancer activity among patients with metastatic breast cancer that has progressed following several prior therapies. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology. Metastatic breast cancer (MBC) refers to cancer that has … Continue reading "Abemaciclib Promising in Advanced Breast Cancer"

Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival (03/28/2016)

Premenopausal women who have been diagnosed with breast cancer have improved survival if their chemotherapy doses are delivered every two weeks, compared to every three weeks. These results were recently presented at the 2016 European Breast Cancer Conference (EBCC-10) in the Netherlands. Chemotherapy following surgery is a standard treatment option for premenopausal women diagnosed with … Continue reading "Dose-Dense Chemotherapy for Premenopausal Breast Cancer Improves Survival"

Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer (03/17/2016)

The United States Food and Drug Administration (FDA) has approved Ibrance (palbociclib) to be used with Faslodex (fulvestrant) for women with hormone-positive (HR-positive), human epidermal growth factor receptor-2 (HER2)-negative, metastatic breast cancer that has progressed following prior endocrine (hormone) therapy. The majority of breast cancers are HR-positive. These cancers are stimulated to grow by the … Continue reading "Ibrance® Approved for Use in Combination with Faslodex® in Hormone-Positive Breast Cancer"

ASCO Publishes Breast Cancer Survivorship Guidelines (01/25/2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated guidelines were recently published in the Journal of Clinical Oncology. There is an estimated 3.1 million breast cancer survivors alive today in the United States. At present, … Continue reading "ASCO Publishes Breast Cancer Survivorship Guidelines"